Season 1, Episode 10 · Released November 17, 2026
For a disease that affects a few hundred children, the math of drug development usually doesn't work, and nobody builds the treatment. The priority review voucher was designed to change that math without sending the bill to taxpayers. In this episode, David Ridley, the Duke economist who proposed it twenty years ago, explains how it works at the kitchen-table level, takes on the evidence for and against it, and describes what happens when Congress waits until the last minute to renew it. We close by looking at a new bipartisan roadmap for FDA modernization that would make the voucher permanent and give patient foundations a bigger role in building the evidence future trials depend on.
A priority review voucher doesn't let a medicine skip any testing. It shortens how long the FDA takes to review the paperwork once testing is done, and a company can sell that faster review to another company for a medicine with a bigger market.
The rare pediatric voucher has never been permanent. Its authority lapsed from December 2024 until February 2026, and it now expires September 30, 2029. Investors watch that date.
If your family lives with a rare disease, get to know the patient foundation for that condition. Foundations often fund the earliest research, and under ideas now circulating in Washington, they could build the evidence the next trial depends on.
Go deeper: Roadmap for FDA Modernization: 12 Bipartisan Ideas to Help Patients and Strengthen American LeadershipStanford Mussallem Center for Biodesign, October 2026.
Related episode: The Patch in the Pipeline (Season 1, Episode 2), where Julie Breneiser first told her community's story.
Apple Podcasts · Spotify · YouTube · Amazon Music · iHeartRadio
Get every new episode by email: sign up here.
This transcript has been lightly edited for readability.
David Ridley: If you're shooting a hundred percent, you're not shooting enough. You've got to take more shots and maybe miss a few of them.
Julie Breneiser: For a family with a young child with a lot of basal cells to have something that would work on 30% of them, or prevent them 30% of the time, that would be a huge, huge win.
David Ridley: So it's weird to think of faster access to medicines as being a bad thing.
Terry Wilcox: That's David Ridley, an economist at Duke University, and Julie Breneiser, who lives with a rare genetic condition called Gorlin syndrome, and whose two children were diagnosed with it when they were young. I'm Terry Wilcox, and this is State of the Patient.
In September, at our Summit in the Kennedy Caucus Room, Patients Rising gave David Ridley our Policy Innovation Award. Twenty years ago, he and two colleagues published a paper in Health Affairs with an idea so simple that people who worked in Congress at the time doubted it could work. A year later, it was law. It's called the priority review voucher. And if you love a child with a rare disease, it is one of the few tools our system has that gives a company a reason to work on a treatment at all. Most people have never heard of it. So David came back on the show to explain it the way you'd explain it at the kitchen table and to tell me honestly whether it works. Then we'll look ahead at a set of ideas now circulating in Washington that would make the voucher permanent and change what the FDA asks of the smallest patient communities.
Here's the problem David set out to solve. Developing a medicine takes years and costs a fortune, and most of that money is spent before anyone knows whether it even works. For a disease that affects millions of people with insurance, the math can work. For a disease that affects a few hundred children, or millions of people in countries with nothing to spend, it usually doesn't. Nobody is the villain in that story. The market simply has no reason to show up. David wanted to give it one without sending the bill to taxpayers.
David Ridley: So, yeah, what was our motivation? We were looking for ways to encourage drug makers to work on diseases that are unprofitable, but really important to treat. And the advantage of the priority review voucher program is that it doesn't directly cost Congress any money. So you don't have to come up with taxes or deficit spending to pay for it. So we're able to encourage drug development for tropical diseases or rare pediatric diseases without the taxpayers directly bearing any burden.
So initially we focused on tropical diseases. A thousand children die each day from malaria. But the voucher program naturally applied to other diseases where we really wanted new product development, but the commercial incentives weren't there. And so rare pediatric diseases are a great example of that. Treatments for rare pediatric diseases are like insurance. What does insurance do? If a very, very unlikely event happens, it helps to make you whole. Well, that's what a drug for a rare pediatric disease does. So if you or a member of your family faces this very unlikely event, a devastating event, potentially devastating event, then we as a society can help you because we've created incentives to develop drugs for these rare diseases.
Terry Wilcox: David's first target was tropical diseases, and in 2012 Congress extended the idea to rare diseases in children. I asked him to explain the voucher the way he would to a parent who had never heard of it. He started with a story from his own campus.
David Ridley: One of my colleagues here at Duke was working on a treatment for a rare pediatric disease. It's a severe form of DiGeorge syndrome where the babies can't make T cells. And without the ability to make T cells, they don't have protection, they don't have an effective immune system, and they don't survive for very long. And so this doctor came up with a treatment for this disease, a biologic for this disease. However, there was no commercial incentive to develop it because it's so rare. She couldn't get money from investors to do the late-stage clinical testing to get FDA approval. Because of the priority review voucher program, she was able to get investors interested in her product. They provided her some money up front. She was able to get FDA approval. She and the investors got the priority review voucher. She and the university got some money. The investors got paid back. And now that product is on the market helping patients.
Terry Wilcox: So a treatment for a few babies a year exists because a voucher gave someone a reason to pay for the hardest part. Now here's how the voucher itself works. The key, David says, is that it always takes two medicines.
David Ridley: Here's how the voucher works. For every voucher, there are two drugs. That's a key point. Two drugs for every voucher. There's the first drug that treats a rare pediatric disease or tropical disease, a disease without much commercial potential. That's the first drug. The second drug is a drug with commercial potential. And the key there is if that drug gets to market faster, starts making money faster, there's a real commercial incentive there. The first drug might be a rare pediatric disease, might be malaria, might be Ebola. The second drug is a cholesterol drug or migraine or HIV or diabetes. And that second drug, if you can get that drug to market faster, say in a few months, if the FDA can speed up its review of the drug maker's paperwork from, say, 10 months to six months, that can be worth $200 million. So that's real money. That's a real incentive. And because of that incentive, that first drug could get some investment up front.
Terry Wilcox: One thing worth saying plainly, because people mix these things up all the time: a priority review voucher doesn't let a medicine skip any testing. It changes how quickly the FDA reads the paperwork once the testing is done.
David Ridley: It's very easy to confuse them. In fact, when people write about priority review, they sometimes say it accelerates a drug, but we have to be careful that we don't confuse priority review with accelerated approval or breakthrough or fast track. So under priority review, the FDA will review a drug maker's paperwork, data submission, in about six months instead of 10. So clinical trials are finished. The drug maker has sent the FDA some files, and the FDA will review it. So the question is, can the FDA review that submission in six months rather than 10? And the answer typically is yes, they can. That's a pretty reasonable timeline. It requires the FDA to do some planning ahead, schedule some meetings in advance, arrange some inspections, but in general, it's very feasible for them to do the review in six months instead of ten.
Terry Wilcox: When the idea reached Congress, its champions were Senator Sam Brownback, a Republican from Kansas, and Senator Sherrod Brown, a Democrat from Ohio. Ellie Dehoney was Senator Brown's legislative director at the time. She's now at Research!America, and she presented David's award at our Summit.
Ellie Dehoney: He had the notion that we can find an incentive that doesn't cost money that actually promotes tropical disease research and development. And that was the beginning. He had first published a proposal for this idea. And it was such a common sense idea that at first I thought, this is never gonna work.
David Ridley: Three professors, Henry Grabowski, Jeff Moe, and I wrote a paper and published in Health Affairs in 2006, 20 years ago. And it was staff like Ellie who got it done. How amazing is that, that Sherrod Brown, a Democrat, worked with Sam Brownback, a Republican, and they made it law just a year after we wrote the paper.
Terry Wilcox: Underneath all of this sits a fair question, and I asked David directly. By the American Society of Gene and Cell Therapy's count, the FDA has awarded 63 rare pediatric vouchers across 47 diseases, and only four of those diseases had an approved treatment before the program began. But a 2019 study in Health Affairs, the same journal that published David's original proposal, reported that it hadn't found an increase in new rare pediatric medicines entering clinical trials after the program started. I asked David how he squares the two. He pulled the paper up on his screen while we talked, and this is how he reads it.
David Ridley: A 2019 paper in Health Affairs showed that the priority review voucher program increased clinical trial activity for rare pediatric disease drugs. It showed with 95% confidence that there were more drugs going from phase one into phase two for rare pediatric diseases after the creation of the priority review voucher program. It then looked at drugs moving from phase two to phase three. For that analysis, it just barely missed 95% confidence. I don't know, let's say it's 90% confidence. Well, the gold standard is 95% confidence. It's a small sample size. There's just not that many companies working on drugs for rare pediatric diseases. Then from phase three to approval, they found no effect. The priority review voucher did not change the number of drugs that went into phase three that later got approved. Well, of course not. Conditional on getting into phase three, the rare pediatric disease voucher program doesn't do anything else. So it encourages companies to work on phase three, but doesn't make the FDA approve the drug. So if we're going to see an effect, we should see the strongest effect for phase one to phase two. They showed it, 95% plus confidence. What about phase two to phase three? Let's say 90% confidence. Pretty confident that it had an effect, but we're not positive because it's a small sample size. It's hard to get statistical significance with a small sample size. And that's the problem.
And you just gave a really powerful statistic, and that is that there are so many more treatments for these rare pediatric diseases than there were before. And there are so many people that you and I talk to that are able to move products forward, are able to get funding, are able to build business models around rare pediatric diseases that weren't able to do so before. So I think the evidence is really quite clear that the rare pediatric disease priority review voucher program has made a difference for drug development and has made a difference for patients.
Terry Wilcox: That's David's reading of the data, and the study's authors were more cautious about the same numbers. I think both can be honest at once. When only a handful of companies are working on a disease, it's very hard for any study to prove much of anything in either direction. Congress has asked the Government Accountability Office to study whether the program works, so we'll have more to go on. The other criticism you'll hear is about cost. If a medicine reaches the market a few months sooner, someone starts paying for it a few months sooner. I put that to David.
David Ridley: It's funny to characterize it as a cost. So critics will say, well, it gets these drugs to market faster and they start making money faster and we have to pay for it. Is that a problem? So is the ideal that these drugs never make it to market and that we never have to pay for them? Is the ideal world that we live in that patients never get new drugs, and thus we don't have to raise insurance premiums to pay for those drugs? The FDA is approving these drugs. Insurers are agreeing to pay for them. I think the vast majority of these have a lot of benefit for patients, or they wouldn't be paid for. The assumption here is that insurers will never say no to a drug that's not very valuable. I think insurers are willing to say no to a lot of drugs. So it's weird to think of faster access to medicines as being a bad thing.
Terry Wilcox: Now, the part that should matter to every family waiting on a trial. The rare pediatric voucher has never been permanent. Congress has to keep renewing it, and the last time it didn't do it in time. The FDA's authority to grant new rare pediatric designations lapsed in December 2024 and wasn't restored until February of this year, with a new expiration date of September 30, 2029. For 14 months, a company deciding whether to start a rare pediatric program couldn't count on the voucher being there at the end. David told me he's confident Congress will renew it again. What worries him is when.
David Ridley: I'm confident that in 2029, Congress will renew it because members of Congress like to help sick children. So I think it will be renewed. I fear, however, that members of Congress will wait until the last minute to do it. There's a fair amount of brinkmanship among members of Congress, and they can use it as leverage for other things. They can say, I'll give you this if you'll give me that. So I'm confident that they'll renew it. I think they might wait till the last minute. Does it matter if they wait until the last minute? Yes, the delays do matter, because some investors are wary of providing funding for that rare pediatric disease drug when there's still some uncertainty. So we see examples where investors wait until after renewal to provide the funding to move into the late-stage clinical trials. So there are drugs for rare pediatric diseases that could start testing in, say, 2028, but they won't, because they're waiting to get the funding that will come after renewal.
Terry Wilcox: There's a proposal on the table to end that cycle. In October, Stanford's Mussallem Center for Biodesign published a report called Roadmap for FDA Modernization: 12 Bipartisan Ideas to Help Patients and Strengthen American Leadership. Its authors are Rohini Kosoglu, a former domestic policy adviser to the Vice President, and Ryan Long of the Paragon Health Institute, a former counsel to the Speaker of the House. Some of you will remember Ryan from our 340B panel at the Summit. Rohini also co-founded a patient foundation for an ultra-rare genetic condition that affects one of her own sons. The twelfth and the last of their ideas is the simplest. Make the rare pediatric voucher permanent, so families and the companies working on their diseases stop living from one deadline to the next. They note that the President's budget request for next year proposes the same thing.
What struck me about the rest of the roadmap is how many of its ideas speak to things you've already heard in the episode. Take Julie Breneiser's community. When I talked with Julie for an earlier episode, she told me two treatments her community had hoped for didn't move forward because they missed the results their trials were measured against. And she said something I haven't stopped thinking about.
Julie Breneiser: And in rare disease, let's take basal cells for an example. We would be okay if a topical medication prevented or treated fewer than 50% of our basal cells. I mean, to have a 30% reduction would be huge for us. I've had over a thousand. So if I knew that there was something out there that was gonna allow me to only have to deal with 700 in my lifetime, that's a big difference.
Terry Wilcox: The roadmap takes on a version of that frustration. A trial can run for years, and in some diseases, the science of what counts as a meaningful result moves before the data come in. The authors propose a structured process set out in advance for the FDA to account for that, and they would take the input of patients and caregivers about what a meaningful change actually looks like and make it a documented part of the agency's review. They're careful to say the standard for proving a medicine works wouldn't change. What would change is that the people living with the disease would have a recorded say in what the trial is measuring. I told David about Julie's community, and what it's like to watch the rug pulled out from under people who have waited years for a trial to read out.
David Ridley: It's brutal. The hope is taken away for the patient, for the drug maker. It's brutal. I'm so grateful that these patients are willing to continue to hope, to continue to try to enroll in the clinical trials, that the investors and drug makers are willing to take a shot at these. Fortunately, it's not just about the money for them, it's about the mission.
Terry Wilcox: The voucher is one tool, and David is the first to say it can't do everything. It rewards a company at the finish line. It does very little for the riskiest early work, before anyone knows whether an idea will hold up.
David Ridley: Yeah, I think sometimes in this space we talk about push funding and pull funding. Push funding is money up front, early, to cover your costs, whether you succeed or not. Pull funding is late stage, a reward for success. So early on, we need to provide grants to drug makers. So the NIH can be a really important source of funding, and of course all of the foundations that have appeared. The foundations play an incredibly important role here in early-stage funding. And then once we get into phase one and then phase two, show some early evidence that it's safe and maybe works, but we haven't proven it in a large clinical trial, then the pull mechanisms like the priority review voucher can pull the drug through. So grants from foundations and the government up front, and we need more of those. And then priority review vouchers or other rewards on the back end, conditional on success. You only get a priority review voucher if your drug gets approved by the FDA.
Terry Wilcox: That point about foundations matters, because the roadmap would give patient foundations a bigger role at the very front of the line. In a disease with only a few hundred patients, a trial often has to compare treated patients against a record of how the disease progresses without treatment, what researchers call natural history. Today, every company builds that record on its own, even when another company has already built one for the same disease, and for many rare diseases, nobody has built it at all. The roadmap proposes letting a patient organization or an academic group get a natural history dataset qualified by the FDA before any company arrives, so that every future program in that disease could use it. Another idea would let patient groups bring a problem that keeps recurring across a field to the FDA and get a public answer, within a set time such as 120 days, about what the agency has already learned. Put simply, the families who know a disease best could start laying the groundwork for a treatment before anyone is selling one.
When I asked David for his last word, he went somewhere I didn't expect at all. Basketball.
David Ridley: I think the accelerated approval program is really misunderstood. Again, don't confuse accelerated approval with priority review. These are different. This is an early approval for a drug based on early evidence that it's safe and works, with later evidence to come. If we don't give any drugs accelerated approval, then we're waiting all of these years to help those patients, and all of these years before we can get any sort of return on investment. It would be like telling Caitlin Clark or Steph Curry, don't shoot unless you're positive you're going to make it. We will only accept a 100% rate on your shot attempts. If you're shooting 100%, you're not shooting enough. You've got to take more shots and maybe miss a few of them. It's funny, because with NIH funding, we understand this. With NIH grants and foundation grants, we understand we're going to give a grant up front. The drug might not work out. In fact, it's probably not going to work out. Most drugs that enter human testing don't ultimately succeed. But that's okay. We understand how that works. Whether it's Caitlin Clark, or whether it's NIH funding, or whether it's accelerated approval, we can't expect a hundred percent success rate, and we shouldn't. We've got to take more shots on goal.
Terry Wilcox: More shots on goal. That's the whole idea in four words, and that's why we honored David this year. Twenty years ago, his voucher went from a journal article to law in about a year, because a Republican and a Democrat decided it made sense. The roadmap's authors are betting on that same kind of agreement, and they point out that several of their ideas have already been put forward by lawmakers in both parties. Making the voucher permanent is the easiest of them to understand. Most of the others come back to what David described: giving more people a reason and a way to take the shot.
If your family lives with a rare disease, find the patient foundation for that condition and get to know it. Under ideas like these, groups like that would be the ones building the evidence the next trial depends on. And when the voucher comes up for renewal, you'll know what's at stake and why waiting until the last minute is never free. We'll be watching which of these ideas move in Washington, and we'll bring them back to you here.
Thank you, David Ridley. Thank you, Julie Breneiser, and to Ellie Dehoney. I'm Terry Wilcox, and this has been State of the Patient. Remember, no one applies for this job. The system hands it to you, so take it. Be the CEO of your own health care and your family's, because there's no plan and there's no helpline coming to save you.